Journal of Oncology Translational Research



Hot spots that can lead therapy

Bhaskar Vyas

DiponEd BioIntelligence, India

Abstract

This is a research innovation that aims to provide an additional therapeutic tool. It will open up a vast panorama of regenerative medicine by application of adipose derived Mesenchymal stem cells (ADMSCs). ADMSCs are selected on account of the large amount available for lipoaspiration and a larger percentage (30%) of Mesenchymal stem cells (MSCs) obtainable there from. The applications in clinical practice extend across mesoderm, endoderm, and ectoderm layers. There are three products that can be derived from the lipoaspirate.

They are (1) stromal vascular fraction (SVF), (2) islet cell aggregates (ICAs) translated from ADMSCs, (3) and ADMSCs with ~95% purity. They are deployed to illustrate the safety and efficacy in clinical trials for (1) mesoderm translation as in osteoarthritis knee, (2) endoderm translation to insulin-producing cells as applicable to diabetes, and (3) ectodermal translation as applicable in retinal blindness as well as in nonhealing indolent ulcers on the skin.

All three products are found safe with no adverse side effects. Proof of concept studies along with initial clinical trials for osteoarthritis, diabetes types I and II, retinal blindness, and nonhealing ulcer of any aetiology have been conducted.

Autologous SVF and ADMSCs are in futuristic domain for conducting clinical trials across all the three germinal layers.

Biography

Bhaskar Vyas is working in Total Potential Cells (P) Ltd. He is credited by the Editor of International Journal of Consciousness Studies as Father of Modern Indian Hypnosis. He has 20 Publications with 50 citations. He is expertise in regenerative medicine and stem cell differentiation.



 $14^{\rm th}$ World Congress on Stem Cell Research, Cell and Gene Therapy October 30, 2020

Citation: Bhaskar Vyas, Hot spots that can lead therapy, Stem Cell Congress 2020, 14th World Congress on Stem Cell Research, Cell and Gene Therapy October 30, 2020, 02